Research suggests that certain weight-loss drugs, including GLP-1 drugs such as Ozempic and Retatrutide, may have an additional benefit of reducing the risk of various types of cancer. Studies have linked these drugs to a lower risk of cancers including pancreatic, colorectal, and breast cancer. The extent to which these drugs can prevent or treat cancer is still being studied, but initial findings indicate a potential connection between GLP-1 weight-loss drugs and reduced cancer risk.